Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders
Launch of Start-up QLi5 Therapeutics
The Lead Discovery Center GmbH (LDC) and the South Korean drug development specialist Qurient have founded QLi5 Therapeutics GmbH, together with their partners, the Max Planck Society (MPG) and Nobel laureate Prof. Huber, emeritus director of the Max Planck Institute for Biochemistry. Dortmund based QLi5 Therapeutics licensed novel proteasome inhibitors from LDC and its partners. QLi5 Therapeutics will advance these towards preclinical and clinical development for the treatment of cancers as well as inflammatory and autoimmune disorders.
The proteasome is a hollow cylinder consisting of 28 subunits, which are shown in color here in the ligament model. Inside the molecule are the active centers as binding sites for various inhibitors (white). The proteasome is degrading proteins that are no longer required and therefore plays an important role in cell regulation. Novel proteasome inhibitors with unique binding characteristics should create the basis for new therapies for the treatment of cancer, inflammation and autoimmune diseases.
Robert Huber, © MPI für Biochemie
The novel proteasome inhibitors were generated within a long standing and successful collaboration between the LDC and Prof. Huber. Combining Prof. Huber’s vast expertise in the field of proteasome with the LDC’s drug discovery capabilities, the partners have created a portfolio of proteasome inhibitors with unique binding characteristics and favourable pharmacodynamic properties. The further development in the joint venture with Qurient is the outcome of a successful strategic partnership between Qurient, LDC and Max Planck.
“The proteasome is a real treasure chest,” Prof. Huber comments, “and the launch of Qli5 Therapeutics enables us to harness its potential for the treatment of many diseases. Our new generation of proteasome inhibitors is set to overcome key challenges that have so far hampered a broader application of the first generation of covalently acting proteasome inhibitors.” The proteasome plays an important role in cell regulation by degrading proteins and represents a well established clinical target for the treatment of liquid tumours, in particular multiple myeloma.
“We believe the LDC’s innovative proteasome inhibitors hold exceptional potential, and we are excited to be part of QLi5 Therapeutics to jointly advance them towards preclinical and clinical testing,” Kiyean Nam, CEO and CSO of Qurient adds. “We very much appreciate the LDC as long-term partner and prime source of external innovation.” Over the last years, Qurient has licensed two other inhibitor projects from the LDC, targeting the kinases, Axl and CDK7 respectively. Both leads have made considerable progress since, e.g. nomination for clinical development.
“The foundation of Qli5 Therapeutics is the current peak of our trustful and long-term collaborations with Prof. Huber and Qurient, our exceptionally strong and committed South Korean partner,” Bert Klebl, CEO and CSO of the LDC comments. “This joint venture is a wonderful step forward in our mutual relationship and it is a great opportunity to translate the potential of the proteasome complex into more tangible benefits for patients.”
“Having previously licensed assets to Qurient, we are delighted to now jointly start-up a venture with Qurient. QLi5 provides excellent prospects to enable a much needed next generation of proteasome inhibitors. Bringing the company on track together with Qurient has been a swift and smooth endeavour”, adds Dieter Link, Licensing Manager at Max Planck Innovation GmbH.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
